Last update 28 Mar 2025

HB-0036

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
anti-TIGIT/anti-PD-L1 bispecific antibody, HB-0036, HB0036
Action
inhibitors
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 2
United States
25 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
China
25 Aug 2022
Locally Advanced Malignant Solid NeoplasmPhase 2
United States
25 Aug 2022
Locally Advanced Malignant Solid NeoplasmPhase 2
China
25 Aug 2022
Esophageal Squamous Cell CarcinomaPhase 1
United States
09 Dec 2022
Esophageal Squamous Cell CarcinomaPhase 1
China
09 Dec 2022
Gastroesophageal junction adenocarcinomaPhase 1
United States
09 Dec 2022
Gastroesophageal junction adenocarcinomaPhase 1
China
09 Dec 2022
Hepatocellular CarcinomaPhase 1
United States
09 Dec 2022
Hepatocellular CarcinomaPhase 1
China
09 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
19
whqwtpftfy(xgnznlsjhl) = ≥10% ukmnywekxj (autxexjmdw )
Positive
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free